<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225143</url>
  </required_header>
  <id_info>
    <org_study_id>UROSTIM</org_study_id>
    <nct_id>NCT04225143</nct_id>
  </id_info>
  <brief_title>Bilateral vs. Unilateral Stimulation in Neurological Bladder Disroders</brief_title>
  <acronym>UROSTIM</acronym>
  <official_title>Efficacité Clinique comparée de la Stimulation transcutanée du Nerf Tibial postérieur unilatérale vs bilatérale Pour Traiter Une hyperactivité vésicale Neurologique Non sévère : Essai Clinique randomisé</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of bilateral stimulation of the tibial nerve compared
      to unilateral stimulation in neurological bladder disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary disorders are common in neurological diseases. The prognosis of neurological bladders
      is twofold. On the one hand, symptoms such as incontinence or retention affect quality of
      life and comfort. On the other hand, complications such as urinary tract infections or renal
      failure threaten health and even involve patients' vital prognosis. Several therapies are
      used to treat these urinary disorders including transcutaneous or percutaneous posterior
      tibial nerve stimulation (SNTP). SNTP is used in treating symptoms of bladder overactivity.
      This treatment is most often used unilaterally, but can be used bilaterally.

      The aim of this study is to evaluate the effectiveness of bilateral stimulation of the tibial
      nerve compared to unilateral stimulation in neurological bladder disorders.

      50 patients will be included, in two arms by randomization, one arm of 25 patients will be
      treated by unilateral stimuylation and the other arm of 25 patients will be trated by
      bilateral stimulation.

      They will be evaluate at 3, 6 and 12 months by auto questionnaire and the effectivess of each
      therapy will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary symptom profile score (USP score)</measure>
    <time_frame>3 months</time_frame>
    <description>auto quastionnaire between 0 and 39 points The higher the score the higher the urinary symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mictional calendar</measure>
    <time_frame>3 months</time_frame>
    <description>records the number of mictions per day and the number of urinary leaks per day over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of improvement (PGI-I)</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire of quality of life improvement :The PGI-I is a transition scale that is a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neurogenic Urinary Bladder, Spastic</condition>
  <arm_group>
    <arm_group_label>bilateral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients with an overactive bladder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unilateral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients with an overactive bladder</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>urostim bilateral</intervention_name>
    <description>Treatment by bilateral neurostimulation of the tibial nerve</description>
    <arm_group_label>bilateral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>urostim unilateral</intervention_name>
    <description>Treatment by unilateral neurostimulation of the tibial nerve</description>
    <arm_group_label>unilateral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals who received research information

          -  Individuals affiliated to a social security scheme

          -  Individuals over 18 years of age

          -  Individuals with non-serious neurological bladder hyperactivity

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hélène LARDREAU</last_name>
    <phone>02 31 06 47 21</phone>
    <email>lardreau-h@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Caen Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joffrey Drigny, MD MSC</last_name>
      <phone>+33231064533</phone>
      <email>drigny-j@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Ruet, MD MSC</last_name>
      <phone>+33231064721</phone>
      <email>ruet-a@chu-caen.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

